300 related articles for article (PubMed ID: 32815766)
1. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
2. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
Gallagher ME; Chawla A; Brady BL; Badawy SM
J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
[TBL] [Abstract][Full Text] [Related]
5. A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease.
Zaidi AU; Glaros AK; Lee S; Wang T; Bhojwani R; Morris E; Donohue B; Paulose J; Iorga ŞR; Nellesen D
Orphanet J Rare Dis; 2021 Nov; 16(1):460. PubMed ID: 34727959
[TBL] [Abstract][Full Text] [Related]
6. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States.
Mvundura M; Amendah D; Kavanagh PL; Sprinz PG; Grosse SD
Pediatr Blood Cancer; 2009 Oct; 53(4):642-6. PubMed ID: 19492318
[TBL] [Abstract][Full Text] [Related]
7. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
8. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
[TBL] [Abstract][Full Text] [Related]
9. Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 32685602
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
11. Association Between Vaso-Occlusive Crises and Opioid Prescriptions Among Patients with Sickle Cell Disease: A Retrospective Claims-Based Study.
Kang HA; Barner JC; Richards KM; Bhor M; Paulose J; Kutlar A
J Health Econ Outcomes Res; 2020; 7(1):94-101. PubMed ID: 36873574
[No Abstract] [Full Text] [Related]
12. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
[TBL] [Abstract][Full Text] [Related]
14. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease.
Rizio AA; Bhor M; Lin X; McCausland KL; White MK; Paulose J; Nandal S; Halloway RI; Bronté-Hall L
Qual Life Res; 2020 Jun; 29(6):1533-1547. PubMed ID: 31933113
[TBL] [Abstract][Full Text] [Related]
15. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and healthcare utilization in patients with sickle cell disease: a nationwide cohort study of Medicaid beneficiaries.
Desai RJ; Mahesri M; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Schneeweiss S
Ann Hematol; 2020 Nov; 99(11):2497-2505. PubMed ID: 32869184
[TBL] [Abstract][Full Text] [Related]
17. National cost of trauma care by payer status.
Velopulos CG; Enwerem NY; Obirieze A; Hui X; Hashmi ZG; Scott VK; Cornwell EE; Schneider EB; Haider AH
J Surg Res; 2013 Sep; 184(1):444-9. PubMed ID: 23800441
[TBL] [Abstract][Full Text] [Related]
18. Impact of Insurance Provider on Overall Costs in Failed Back Surgery Syndrome: A Cost Study of 122,827 Patients.
Elsamadicy AA; Farber SH; Yang S; Hussaini SMQ; Murphy KR; Sergesketter A; Suryadevara CM; Pagadala P; Parente B; Xie J; Lad SP
Neuromodulation; 2017 Jun; 20(4):354-360. PubMed ID: 28322477
[TBL] [Abstract][Full Text] [Related]
19. The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US.
Shafrin J; Thom HHZ; Keeney E; Gaunt DM; Zhao LM; Bhor M; Rizio AA; Bronté-Hall L; Shah N
Curr Med Res Opin; 2021 May; 37(5):761-768. PubMed ID: 33686891
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]